Cuba’s Lung Cancer Vaccine CIMAvax-EGF: What It Does, Who Can Get It in the US
CIMAvax-EGF, the so-called Cuban lung cancer vaccine, is not a shot that prevents cancer and it is not approved by the FDA. It is a therapeutic immunotherapy for advanced non-small cell lung cancer (NSCLC), developed in Havana, that in Cuban trials added a few months of median survival and helped a minority of patients live for years.
In the United States, the only legal way to receive it is through a clinical trial at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Traveling to Cuba to get it is a legal gray zone that got tighter after new Treasury rules took effect on September 30, 2026. Here is what the drug is, what the evidence shows, and what American patients and families can realistically do.
Updated October 19, 2026
CIMAvax-EGF at a Glance
| Question | Short answer |
|---|---|
| What is it? | A therapeutic cancer immunotherapy for advanced NSCLC, not a preventive vaccine |
| Who developed it? | Cuba’s Center for Molecular Immunology (CIM), Havana |
| Registered in Cuba | 2008 |
| Patients treated worldwide | More than 5,000, according to Roswell Park |
| Approved where? | Cuba, Argentina, Bosnia and Herzegovina, Colombia, Kazakhstan, Paraguay, Peru; Belarus registered it in July 2024 |
| FDA-approved? | No. Available in the US only inside Roswell Park clinical trials |
| Best survival data | Cuban phase III: median 10.83 vs. 8.86 months; 5-year survival 14.4% vs. 7.9% |
| Can Americans travel to Cuba for it? | There is no OFAC travel category for medical treatment; tourism is banned |
What CIMAvax-EGF Is (and What It Isn’t)
The word “vaccine” causes most of the confusion. CIMAvax does not stop healthy people from getting cancer, and it does not attack tumor cells directly. It trains the patient’s immune system to make antibodies against epidermal growth factor (EGF), a protein that lung tumors use to grow.
As Roswell Park explains on its CIMAvax page, those antibodies lower the amount of EGF circulating in the blood, starving cancer cells of a growth signal. The goal is to keep tumors stable for longer, not to make them disappear.
What’s Inside
According to a 2017 review by CIM researchers in Frontiers in Immunology, the formula combines human recombinant EGF with P64K, a carrier protein from the bacterium Neisseria meningitidis, plus an adjuvant called Montanide ISA 51. Because EGF is a protein the body already makes, the immune system ignores it on its own; the carrier protein is what makes it react.
Where It Fits in Treatment
CIMAvax is used after first-line chemotherapy in patients with stage IIIB or IV NSCLC. In the Cuban phase III trial, patients had completed four to six cycles of platinum-based chemotherapy before starting. It works as a maintenance therapy: something to slow the disease once the initial treatment is done.
How the Treatment Works, Step by Step
- Medical review. A multidisciplinary oncology team reviews the patient’s records and confirms the diagnosis and stage.
- Pre-treatment. In the Cuban protocol, patients get a single low dose of cyclophosphamide (200 mg/m²) before vaccination, to help the immune response.
- Induction phase. Four doses, given every two weeks. Each dose is split into intramuscular injections at four sites (both arms and both legs in the Roswell Park protocol).
- Maintenance. Monthly booster doses for as long as the doctors consider it useful.
- Monitoring. Blood tests track antibody levels against EGF and how much EGF is left in circulation.
A common mistake: assuming one trip to Cuba is enough. The monthly boosters are part of the schedule, which is why some American patients in past years carried refrigerated doses home, a practice that raises its own legal questions (see below).
What the Evidence Actually Shows
This is the section most English-language articles skip. The headline claims (“Cuba cured lung cancer”) are wrong, but the data are not nothing.
| Cuban phase III trial (405 patients, 2:1 randomization) | CIMAvax | Control |
|---|---|---|
| Median overall survival, all patients | 10.83 months | 8.86 months |
| Median survival, patients who completed induction | 12.43 months | 9.43 months |
| Median survival, high baseline EGF (>870 pg/ml) | 14.66 months | 8.63 months |
| 5-year survival, all patients | 14.4% | 7.9% |
| 5-year survival, high baseline EGF | 23% | 0% |
Source: Saavedra and Crombet, Frontiers in Immunology, 2017. The trial enrolled 270 vaccinated patients and 135 controls at 21 sites.
Three things to keep in mind when reading those numbers:
- The median gain is modest. About two months for the whole group, roughly six months for patients with high EGF levels in their blood.
- The long tail is the interesting part. Nearly twice as many vaccinated patients were alive at five years. That is what drew the attention of American researchers.
- The trial was open-label. Patients and doctors knew who got the drug. That does not invalidate the results, but it is one reason US regulators want their own trials.
Side Effects
The Cuban trials reported mostly mild to moderate reactions: pain at the injection site, fever, headache, chills, vomiting or nausea, and general malaise. Some patients in later studies reported shortness of breath. The review does not give percentages, so be wary of any website claiming “zero side effects.”
CIMAvax in the United States: The Roswell Park Trials
Roswell Park Comprehensive Cancer Center is the only US institution cleared by the FDA to test CIMAvax. Its partnership with CIM started in 2011, the first US trials began in 2017, and in 2018 the two created a joint venture, Innovative Immunotherapy Alliance. The Roswell Park Alliance Foundation committed $4 million in donor funds to the first trials.
| Study | What it tests | Status |
|---|---|---|
| Phase I/II (NCT02955290) | CIMAvax + nivolumab or pembrolizumab in advanced NSCLC and head and neck cancer | Phase I completed: safe in 13 patients; first trials now closed |
| Prevention study (NCT04298606) | CIMAvax in high-risk adults 50 to 79 and lung cancer survivors (stage up to IIIA) | Early-phase; contact Roswell Park for enrollment |
| Phase II (NCT07543172) | CIMAvax + sotorasib or adagrasib in KRAS G12C-mutated advanced NSCLC | First posted April 2026; listed as not yet recruiting; target 29 patients |
| Colorectal study | CIMAvax + standard therapy in RAS/BRAF wild-type metastatic colorectal cancer | Phase 0 |
The newest trial, NCT07543172 on ClinicalTrials.gov, pairs CIMAvax with KRAS G12C inhibitors, a class of targeted pills now used for a specific mutation in lung cancer. It is led by Dr. Grace Dy, the same investigator who ran the nivolumab combination. The plan includes an 8-week loading phase, 12 months of maintenance and 4 months of follow-up.
The prevention study is the most ambitious idea. Roswell Park describes it as a test of whether CIMAvax can change biomarkers in the lungs of heavy former smokers and survivors. “We have strong preliminary evidence that this stalls the growth of lung tumors,” said Mary Reid, the center’s chief of cancer screening. No results have been published yet.
How to Ask About Enrollment
Call 1-800-ROSWELL (1-800-767-9355) or ask your oncologist to send a referral. Roswell Park warns that trial participation requires spending extended periods in Buffalo. Eligibility depends on the specific trial, the cancer type, mutations and prior treatments, so do not assume you qualify until the trial team reviews your records.
Can Americans Travel to Cuba for CIMAvax?
Short answer: not under any travel category designed for it. US law still bans tourist travel to Cuba, and medical treatment is not one of the 12 categories of authorized travel listed in the Treasury Department’s Cuba sanctions FAQs.
For years, some patients went under the “people-to-people” educational category. That door is now closed. Effective September 30, 2026, the Office of Foreign Assets Control (OFAC) removed the general authorization for group people-to-people travel (except for grandfathered trips booked before that date) and for professional meetings in Cuba. The remaining categories, such as support for the Cuban people or professional research, come with full-time schedules and documentation requirements that do not match a patient’s medical stay.
The Payment Problem
Medical services for foreigners in Cuba are sold by state-run companies. The new OFAC rule also bars indirect financial transactions with entities on the State Department’s Cuba Restricted List. Before paying any Cuban provider, check that list and talk to a sanctions attorney. We are not lawyers, and this is not legal advice.
Bringing Doses Back
Two separate sets of rules apply. OFAC allows authorized travelers to bring back Cuban-origin goods for personal use as accompanied baggage (alcohol and tobacco excluded). But the FDA controls whether an unapproved drug can enter the country. Its personal importation policy may tolerate it only if the drug treats a serious condition with no effective US alternative, the quantity is no more than a three-month supply, you state in writing it is for personal use, and you bring a letter from a doctor or name a US-licensed physician who will supervise the treatment. This is enforcement discretion, not a right.
What It Cost American Patients
Cuba’s state medical services company, Comercializadora de Servicios Médicos Cubanos (CSMC), lists CIMAvax and a second lung cancer drug, Vaxira, in its programs for stage IIIB and IV NSCLC. As of its July 2025 post, it does not publish prices: patients get a cost estimate after sending their records.
The most detailed public figures are older. A 2018 Pulitzer Center investigation found that:
| Item (2018 figures) | Reported cost |
|---|---|
| One dose (four injections) | About $860 (USD) |
| Full trip: airfare, lodging, doses to take home | Often more than $10,000 (USD) |
| One patient’s total reported spending | About $16,000 (USD) |
Most Americans were treated at La Pradera International Health Center in Havana, which saw 50 American patients in 2016 and 47 in the first eight months of 2017. Patients stayed about four days for the first dose. Treat these numbers as historical: prices, exchange rules and US policy have all changed since then.
Myths vs. Facts
| Claim you’ll see online | What the record shows |
|---|---|
| “Cuba has a vaccine that cures lung cancer” | It extends survival for some patients with advanced disease; it is not a cure |
| “It prevents lung cancer” | Not proven. Prevention is only being tested in an early-phase Roswell Park study |
| “It’s been approved in the US since 2022” | False. It is not FDA-approved; it is available only in trials |
| “It has no side effects” | Mostly mild, but trials report fever, chills, headache, nausea and injection-site pain |
| “Cubans get it for free” | Yes: it has been free for Cuban patients since 2011, per the Pulitzer Center report |
Why a Cuban Drug Matters to US Science
CIM began the CIMAvax project in 1992 and ran its first clinical trials in 1996. When Cuba registered the drug in 2008, project leader Gisela González called it the first vaccine of its kind registered in the world. Collaboration with Roswell Park began in 2011, but it took until 2017 for the first US trial to open, under the long shadow of the embargo.
The bigger question for American oncologists is not whether CIMAvax works on its own, but whether it adds something when combined with the drugs US patients already receive. Lung cancer care has changed a lot since the Cuban trials, which is why every current Roswell Park study pairs CIMAvax with a modern therapy. As Dr. Igor Puzanov of Roswell Park put it in 2018: “We know what the vaccine is supposed to do. It’s just too early to say if it does it.”
Cuba keeps promoting its cancer portfolio. In April 2026, Cuban state media reported an innovation award for Vaxira (racotumomab), CIM’s other lung cancer vaccine, claiming more than 1,300 patients treated between 2013 and 2023. Those figures come from Cuban official sources and have not been independently verified.
Safety and Scam Warnings
- Do not buy CIMAvax online. It is a refrigerated biologic made only in Cuba. Any website shipping it to your door is a red flag.
- Be careful with “medical tourism” brokers. Some agencies bundle flights, hotels and treatment. Ask what travel category they claim, who receives your money and whether that entity is on the Cuba Restricted List.
- Tell your oncologist. Patients in the past hid the treatment from their doctors. US oncologists have flagged the lack of oversight as their main safety concern.
- Do not stop proven treatment. CIMAvax was tested after chemotherapy, never as a replacement for it.
Practical Tips for Families
- Start with a US trial search. Ask your oncologist to check ClinicalTrials.gov for CIMAvax and other EGF-targeting studies before thinking about travel.
- Gather records early: pathology report, staging, mutation testing (EGFR, KRAS, PD-L1) and treatment history. Every program will ask for them.
- If a relative lives in Cuba, the drug is part of the public health system there and is free for Cuban patients. Ask their oncologist whether they qualify.
- If you plan any trip to Cuba, review the current Cuban customs rules and fill out the D’Viajeros entry form before you fly.
Related Reading
- Can US citizens travel to Cuba? The legal categories explained
- Cuba’s new health law and what it changes
- Fact-checked facts about Cuba
Frequently Asked Questions
Is the Cuban lung cancer vaccine FDA-approved?
No. CIMAvax-EGF has not been approved by the FDA. In the United States it is available only to patients accepted into clinical trials at Roswell Park Comprehensive Cancer Center in Buffalo, New York.
Does CIMAvax prevent lung cancer?
There is no evidence yet that it does. It is approved abroad as a treatment for advanced non-small cell lung cancer. An early-phase Roswell Park study is testing whether it can lower risk in high-risk people, with no published results so far.
How much does CIMAvax cost?
Cuba’s medical services company does not publish prices. A 2018 report put one dose at about $860 and a full trip with take-home doses at over $10,000. Those figures are outdated and should be treated only as a reference.
Can I legally travel to Cuba for cancer treatment?
There is no OFAC travel category for medical treatment, and tourism is prohibited. Since September 30, 2026, people-to-people group travel is no longer generally authorized. Consult a sanctions attorney before planning a trip.
How long does CIMAvax extend life?
In the Cuban phase III trial, median survival rose from 8.86 to 10.83 months. Patients with high blood EGF levels did better, and about twice as many vaccinated patients were alive at five years.
What are the side effects of CIMAvax?
Most reactions are mild to moderate: injection-site pain, fever, chills, headache, nausea or vomiting and general malaise. Some patients reported shortness of breath in later studies.
Which countries have approved CIMAvax?
Roswell Park lists Cuba, Argentina, Bosnia and Herzegovina, Colombia, Kazakhstan, Paraguay and Peru. Belarus registered it in July 2024, according to Cuban officials.
How do I join a CIMAvax clinical trial in the US?
Call Roswell Park at 1-800-767-9355 or ask your oncologist for a referral. The newest trial combines CIMAvax with KRAS G12C inhibitors and requires that specific mutation.
Can I bring CIMAvax from Cuba into the US?
The FDA may allow up to a three-month supply of an unapproved drug for a serious condition with no US alternative, with a doctor’s letter. It is a matter of FDA discretion, and OFAC travel rules apply separately.
Is CIMAvax a type of immunotherapy?
Yes. It is an active immunotherapy: instead of giving antibodies, it prompts the patient’s own body to make antibodies against EGF, a growth signal lung tumors depend on.
This article was updated on October 19, 2026, with the current status of Roswell Park’s trials and the OFAC rule of September 30, 2026. It is for information only and is not medical or legal advice. Sources: Roswell Park Comprehensive Cancer Center, Frontiers in Immunology, ClinicalTrials.gov, US Treasury (OFAC), US Department of State, FDA and the Pulitzer Center.
